Cellceutix Corporation to Present at Biotech Showcase

Cellceutix Receives IRB Approval for Phase 2b Trial of Novel Antibiotic Brilacidin

BEVERLY, MA—January 13, 2014 – Cellceutix Corporation (OTCQB: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, today announced that the Company  will be presenting a corporate overview at the Biotech Showcase(TM) 2014 on Wednesday, January 15th, at 10:30 a.m. PST. The conference is being held in San Francisco at the Parc 55 Wyndham Union Square Hotel.

Interested parties may access the live webcast of the presentation at: http://cellceutix.com/events/.

The Company is also updating shareholders that it has received Institutional Review Board (“IRB”) approval for the Company’s Phase 2b clinical trial of its novel antibiotic Brilacidin as a drug candidate for Acute Bacterial Skin and Skin Structure Infections (“ABSSSI”). Further details will be forthcoming at the Biotech Showcase presentation.